GenomeFrontier Therapeutics, Inc., leverages four proprietary non-viral gene and cell engineering technologies in the chimeric antigen receptor (CAR) T cell therapies for cancer treatment. To demonstrate our disruptive CAR-T cell therapeutic platforms with high efficiency, high safety, and cost competitive, the 1st pipeline GF-CART01 development is undergoing which targets on CD19/CD20-positive lymphoma to streamline these four platforms, then followed by our ultimate goal to conquer solid tumors.  Through collaborating with the global elites, these platforms can be adapted to various CAR-immune cellular gene therapies in autologous as well as allogeneic approaches.